Enanta Pharmaceuticals (ENTA) EBIAT (2016 - 2025)
Historic EBIAT for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q3 2025 value amounting to -$18.7 million.
- Enanta Pharmaceuticals' EBIAT rose 3512.13% to -$18.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$81.9 million, marking a year-over-year increase of 2943.34%. This contributed to the annual value of -$81.9 million for FY2025, which is 2943.34% up from last year.
- According to the latest figures from Q3 2025, Enanta Pharmaceuticals' EBIAT is -$18.7 million, which was up 3512.13% from -$18.3 million recorded in Q2 2025.
- In the past 5 years, Enanta Pharmaceuticals' EBIAT registered a high of -$18.3 million during Q2 2025, and its lowest value of -$39.1 million during Q2 2023.
- Moreover, its 5-year median value for EBIAT was -$28.1 million (2023), whereas its average is -$27.6 million.
- In the last 5 years, Enanta Pharmaceuticals' EBIAT crashed by 26711.07% in 2021 and then soared by 4199.92% in 2024.
- Over the past 5 years, Enanta Pharmaceuticals' EBIAT (Quarter) stood at -$30.1 million in 2021, then rose by 3.75% to -$29.0 million in 2022, then dropped by 15.25% to -$33.4 million in 2023, then soared by 33.28% to -$22.3 million in 2024, then grew by 16.11% to -$18.7 million in 2025.
- Its EBIAT was -$18.7 million in Q3 2025, compared to -$18.3 million in Q2 2025 and -$22.6 million in Q1 2025.